Brief Title
A Progressive Resistance Training Program in Patients With Haemophilia
Official Title
The Impact of Progressive Resistance Training on Quality of Life in Patients With Haemophilia
Brief Summary
This study evaluates the clinical impact of a progressive resistance training program in adults patients with haemophilia
Detailed Description
The training program aims improving muscular strength and endurance in the relevant muscles and joints (knee, elbow, ankle, shoulder and hip) in order to improve the quality of life in the patients.
Study Type
Interventional
Primary Outcome
Change in Muscle strength
Secondary Outcome
Change in Timed Up and Go
Condition
Haemophilia
Intervention
Progressive resistance training
Study Arms / Comparison Groups
Training group
Description: Each subject will participate in 2 sessions each week during 8 weeks, with 3 days of difference (rest) between the sessions.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Other
Estimated Enrollment
20
Start Date
October 24, 2017
Completion Date
June 25, 2018
Primary Completion Date
June 25, 2018
Eligibility Criteria
Inclusion Criteria: - diagnosis of haemophilia A or B - willingness to exercise twice a week during the training program and to complete the pre- and post-program evaluations - approval by their hematologist to participate in the exercise program - age between 18 and 60 years - informed consent signed. Exclusion Criteria: - the inability to attend exercise sessions at least twice a week for 6 consecutive weeks - non adherence to instruction on proper exercise technique - surgical procedures performed 6 weeks prior to or during the exercise program - participation in any other form of exercise, including rehabilitation, during the study; (5) changes in medication during the study - a major bleeding episode that posed a risk or prevented exercise - History of FVIII inhibitor (titer ≥ 0.6 BU [Bethesda unit]) or detectable FVIII inhibitors at screening (titer ≥ 0.4 BU) - Another haemostatic defect - Need for major surgery - Withdrawal of informed consent
Gender
Male
Ages
18 Years - 60 Years
Accepts Healthy Volunteers
No
Contacts
Felipe Querol-Fuentes, MD, PhD, ,
Location Countries
Spain
Location Countries
Spain
Administrative Informations
NCT ID
NCT02781233
Organization ID
H15-29504
Responsible Party
Principal Investigator
Study Sponsor
University of Valencia
Collaborators
Shire
Study Sponsor
Felipe Querol-Fuentes, MD, PhD, Principal Investigator, University of Valencia
Verification Date
October 2018